Small bowel metastasis from pancreatic cancer in a long‑term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review

Fasano,Morena; Corte,Carminia Maria Della; Vicidomini,Giovanni; Scotti,Valerio; Rambaldi,Pier Francesco; Fiorelli,Alfonso; Accardo,Marina; De Vita,Ferdinando; Santini,Mario; Ciardiello,Fortunato; Morgillo,Floriana

doi:10.3892/ol.2016.5279

Small bowel metastasis from pancreatic cancer in a long‑term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review

Authors:
- Morena Fasano
- Carminia Maria Della Corte
- Giovanni Vicidomini
- Valerio Scotti
- Pier Francesco Rambaldi
- Alfonso Fiorelli
- Marina Accardo
- Ferdinando De Vita
- Mario Santini
- Fortunato Ciardiello
- Floriana Morgillo
View Affiliations

Affiliations: Division of Medical Oncology, Department of Clinical and Experimental Medicine ‘F. Magrassi e A. Lanzara’, Second University of Naples, I-80131 Naples, Italy, Thoracic Surgery Unit, Second University of Naples, I-80131 Naples, Italy, Malzoni Radiosurgery Center, Neuromed Group, Agropoli, I-84100 Salerno, Italy, Department of Nuclear Medicine Division, Second University of Naples, I-80131 Naples, Italy, Department of Morphopathology, Second University of Naples, I-80131 Naples, Italy
Published online on: October 18, 2016 https://doi.org/10.3892/ol.2016.5279
Pages: 4505-4509
Copyright: © Fasano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diffuse malignant pleural mesothelioma (MPM) is an aggressive tumor that originates from the surface of the pleura. Approximately 70% of cases are associated with chronic asbestos exposure. MPM is regarded as an incurable disease, with a median survival of ~2 years following intensive multimodality treatment. Pancreatic cancer is a malignancy also associated with a poor prognosis, with only 2% of patients surviving for 5 years. The majority of patients with pancreatic cancer are diagnosed with an advanced stage of disease and experience a poor response to therapy. The development of synchronous MPM and other types of cancer is rare. The present study describes a patient with synchronous, biphasic MPM and pancreatic adenocarcinoma, who was treated with a multimodal therapeutic approach with stereotactic body radiation therapy. Due to a suspected diagnosis of ‘acute abdomen’, an emergency small intestine resection was performed and a subsequent diagnosis of moderately‑differentiated adenocarcinoma was confirmed. During a further immunohistochemical examination, pathologists determined that the small bowel metastasis descended from pancreatic cancer. The onset of bowel metastasis is an event rarely associated with MPM, and has not been previously described in the literature for cases of pancreatic cancer. Therefore, to the best of our knowledge, the present study describes the first case of intestinal metastasis from pancreatic cancer in a long‑term survival patient with biphasic MPM.

View Figures

View References

1	Teta MJ, Mink PJ, Lau E, Sceurman BK and Foster ED: US mesothelioma patterns 1973–2002: Indicators of change and insights into background rates. Eur J Cancer Prev. 17:525–534. 2008. View Article : Google Scholar : PubMed/NCBI
2	Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, et al: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
3	Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA and O'Byrne KJ: Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax. 55:731–735. 2000. View Article : Google Scholar : PubMed/NCBI
4	Opitz I: Management of malignant pleural mesothelioma - the European experience. J Thorac Dis. 6:(Suppl 2). S238–S252. 2014.PubMed/NCBI
5	Baldini EH: Radiation therapy options for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 21:159–163. 2009. View Article : Google Scholar : PubMed/NCBI
6	Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
7	van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C and Giaccone G: European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 23:6881–6889. 2005. View Article : Google Scholar : PubMed/NCBI
8	Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D and Steele JP: The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 63:94–97. 2009. View Article : Google Scholar : PubMed/NCBI
9	van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz M and Giaccone G: European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group: A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European organization for research and treatment of cancer lung cancer cooperative group. Cancer. 85:2577–2582. 1999. View Article : Google Scholar : PubMed/NCBI
10	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
11	Brunner TB and Scott-Brown M: The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol. 5:642010. View Article : Google Scholar : PubMed/NCBI
12	Ghosn M, Kourie HR, El Karak F, Hanna C, Antoun J and Nasr D: Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol. 20:2352–2357. 2014. View Article : Google Scholar : PubMed/NCBI
13	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
14	Belli C, Cereda S and Reni M: Role of taxanes in pancreatic cancer. World J Gastroenterol. 18:4457–4465. 2012. View Article : Google Scholar : PubMed/NCBI
15	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
16	Saif MW: U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane^®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP. 14:686–688. 2013.PubMed/NCBI
17	Kothari N, Saif MW and Kim R: First-line treatment for advanced pancreatic cancer. JOP. 14:129–132. 2013.PubMed/NCBI
18	Attanoos RL, Thomas DH and Gibbs AR: Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals. Histopathology. 43:387–392. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bianchi C, Bianchi T and Ramani L: Malignant mesothelioma of the pleura and other malignancies in the same patient. Tumori. 93:19–22. 2007.PubMed/NCBI
20	Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE and Giaccone G: Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 16:145–152. 1998.PubMed/NCBI
21	Raucci R, Colonna G, Guerriero E, Capone F, Accardo M, Castello G and Costantini S: Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim Biophys Acta. 1814:513–522. 2011. View Article : Google Scholar : PubMed/NCBI
22	Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
23	Robinson BW, Musk AW and Lake RA: Malignant mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
24	Zhang W, Wu X, Wu L, Zhang W and Zhao X: Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med. 3:1822015.PubMed/NCBI
25	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
26	Agaimy A and Wünsch PH: Epithelioid and sarcomatoid malignant pleural mesothelioma in endoscopic gastric biopsies: A diagnostic pitfall. Pathol Res Pract. 202:617–622. 2006. View Article : Google Scholar : PubMed/NCBI
27	Chen HC, Tsai KB, Wang CS, Hsieh TJ and Hsu JS: Duodenal metastasis of malignant pleural mesothelioma. J Formos Med Assoc. 107:961–964. 2008. View Article : Google Scholar : PubMed/NCBI
28	Huang YJ, Wu MH and Lin MT: Multiple small-bowel intussusceptions caused by metastatic malignant melanoma. Am J Surg. 196:e1–e2. 2008. View Article : Google Scholar : PubMed/NCBI
29	Eo WK, Kim GY and Choi SI: A case of multiple intussusceptions in the small intestine caused by metastatic renal cell carcinoma. Cancer Res Treat. 40:97–99. 2008. View Article : Google Scholar : PubMed/NCBI
30	Terashita S, Hirano K, Hirai T, Narabayashi T, Hara Y, Mori H, Endo K and Hirabayashi M: A case of malignant pleural mesothelioma with gastrointestinal metastases which were diagnosed by endoscopic biopsy. Nihon Kokyuki Gakkai Zasshi. 47:133–138. 2009.(In Japanese). PubMed/NCBI
31	Gocho K, Isobe K, Kaburaki K, Honda Y, Mitsuda A, Akasaka Y, Shimada N, Takagi K and Homma S: Malignant pleural mesothelioma presenting as an acute surgical abdomen due to metastatic jejunal perforation. Intern Med. 49:597–601. 2010. View Article : Google Scholar : PubMed/NCBI
32	Liu H, Cheng YJ, Chen HP, Hwang JC and Chang PC: Multiple bowel intussusceptions from metastatic localized malignant pleural mesothelioma: A case report. World J Gastroenterol. 16:3984–3986. 2010. View Article : Google Scholar : PubMed/NCBI
33	Martínez Caselles A, Baños Madrid R, Egea Valenzuela J, Molina Martínez J and Carballo Álvarez F: Gastrointestinal bleeding secondary to duodenal metastases of malignant pleural mesothelioma. Rev Esp Enferm Dig. 102:602–603. 2010. View Article : Google Scholar : PubMed/NCBI
34	de Vin T, Engels B, Gevaert T, Storme G and De Ridder M: Stereotactic radiotherapy for oligometastatic cancer: A prognostic model for survival. Ann Oncol. 25:467–471. 2014. View Article : Google Scholar : PubMed/NCBI
35	Alongi F, Arcangeli S, Filippi AR, Ricardi U and Scorsetti M: Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 17:1100–1107. 2012. View Article : Google Scholar : PubMed/NCBI